Celecoxib upregulates ULBP-1 expression in lung cancer cells via the JNK/PI3K signaling pathway and increases susceptibility to natural killer cell cytotoxicity

Lung cancer has the highest cancer mortality rate in the world, and effective therapies are still required. Cyclooxygenase-2 (COX-2) is highly expressed in numerous types of cancer, and is therefore considered a possible target of cancer treatment. Celecoxib, a selective COX-2 inhibitor, has binding...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jayoung, Noh, Min Hye, Hur, Dae Young, Kim, Bomi, Kim, Yeong Seok, Lee, Hyun-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520723/
https://www.ncbi.nlm.nih.gov/pubmed/33014157
http://dx.doi.org/10.3892/ol.2020.12142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520723/
https://www.ncbi.nlm.nih.gov/pubmed/33014157
http://dx.doi.org/10.3892/ol.2020.12142

Ejemplares similares